Has Gregg Franklin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $106,915 in general payments to Gregg Franklin, MD across 173 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregg Franklin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregg Franklin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregg Franklin, MD

Radiation Oncology · Albuquerque, NMNPI 1124018353

Payments from drug & device makers

$106,915in general payments, 2019–2025

Across 173 payments — averaging $618.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bayer$40K
Eli Lilly$32K
Novartis$16K
Varian Medical Systems, Inc.$8K
Q Biomed Inc.$2K
AstraZeneca$2K
plus $6K from 45 others

$1,017in research payments, 2019–2025

Across 1 payment — averaging $1016.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$1K

What the payments were for

Consulting fees$33,24344%
Speaking & faculty fees$27,95437%
Travel & lodging$7,80910%
Food & beverage$5,7318%
Education$1200%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bayer	57	$40,012
Eli Lilly	2	$32,059
Novartis	18	$16,085
Varian Medical Systems, Inc.	11	$8,498
Q Biomed Inc.	2	$2,429
AstraZeneca	4	$1,669
Siemens Medical Solutions USA, Inc.	4	$1,105
E.r. Squibb & Sons, L.L.C.	8	$821
Medtronic	5	$632
Bard Peripheral Vascular, Inc.	1	$599
Johnson & Johnson(2 entities)	5	$370
Teleflex LLC	1	$350
IBA Proton Therapy, Inc.	1	$159
Sanofi	2	$155
Progenics Pharmaceuticals, Inc.	2	$154
Lilly USA, LLC	3	$154
Puma Biotechnology, Inc.	3	$151
Boston Scientific	2	$142
Stemline Therapeutics Inc.	2	$141
Regeneron Healthcare Solutions, Inc.	3	$127
Blue Earth Diagnostics	1	$123
Merit Medical Systems Inc	1	$83
Sensus Healthcare, Inc.	3	$82
Janssen Scientific Affairs, LLC	1	$76
Sumitomo Pharma America, Inc.	1	$64
Visionrt, Inc.	1	$57
Elekta, Inc.	1	$48
Gilead	2	$47
Eisai Inc.	2	$42
Incyte Corporation	2	$35
EMD Serono, Inc.	2	$35
Bioprotect Medical, Inc.	1	$33
Exelixis Inc.	1	$32
Myovant Sciences Inc.	1	$30
Genmab U.S., Inc.	1	$27
G1 Therapeutics, Inc.	1	$24
Beigene USA, Inc.	1	$22
Merck	1	$21
Pfizer	1	$21
Blueprint Medicines Corporation	1	$20
Epizyme, Inc.	1	$19
Palette Life Sciences, Inc.	1	$19
Daiichi Sankyo Inc.	1	$18
Karyopharm Therapeutics Inc.	1	$18
Taiho Oncology, Inc.	1	$17
Novocure Inc.	1	$16
Aurobindo Pharma USA, Inc.	1	$16
Jazz Pharmaceuticals Inc.	1	$16
Amgen	1	$15
Ipsen Biopharmaceuticals, Inc	1	$15
Rigel Pharmaceuticals, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Xofigo$39,265
PLUVICTO$9,571
Other$4,600
STRONTIUM CHLORIDE Sr-89$2,400
TAGRISSO$1,510
Barrigel$350
INTELLIS$275
Varian Ethos Treatment Planning$160
TrueBeam$160
OSTEOCOOL RF ABLATION SYSTEM$144
TheraSphere Y90 Glass Microspheres 10 GBq$129
LIBTAYO$125
VERZENIO$124
POSLUMA$123
IMBRUVICA$121
Orserdu$120
Nubeqa$116
Breyanzi$115
ELIQUIS$109
Real-time Position Management System$109

How this compares

$106,915 in reported general payments places this provider in the 95th percentile of 24 radiation oncology providers in New Mexico.

See all radiation oncology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$2,433,285

Medicare patients

290

Services billed

12,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tolterodine Tartrate	13	$1,059
Tamsulosin Hcl	69	$974
Ciprofloxacin Hcl	37	$231
Lidocaine-PrilocaineLidocaine/Prilocaine	11	$149

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Albuquerque

David LeeAlbuquerque$30K
Mary BucciAlbuquerque$1K
Patrick BeagenAlbuquerque$1K
Thomas SchroederAlbuquerque$811
Jeremiah JohnsonAlbuquerque$770
Utkarsh ShuklaAlbuquerque$531
Paul AnthonyAlbuquerque$378
Ramesh GopalAlbuquerque$367
Benny LiemAlbuquerque$163
Amanda StoryAlbuquerque$138

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →